Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
An algorithm based testing for Fatty Liver Disease
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Subscribe To Our Newsletter & Stay Updated
